To identify materials and processes which effect supersaturation of the GI milieu for low solubility drugs in order to increase oral bioavailability.
A variety of small and polymeric molecules were screened for their ability to inhibit drug precipitation in supersaturated solutions. The best polymeric materials were utilized to create spray-dried dispersions (SDDs) of drug and polymer, and these were tested for drug form and homogeneity. Dispersions were tested in vitro for their ability to achieve and maintain drug supersaturation, for a variety of drug structures.
Of the 41 materials tested, HPMCAS was the most effective at maintaining drug supersaturation. Drug/HPMCAS SDDs were consistently more effective at achieving and maintaining drug supersaturation in vitro than were SDDs prepared with other polymers. Drug/HPMCAS SDDs were effective in vitro for eight low solubility drugs of widely varying structure. Drug/HPMCAS SDDs were more effective at achieving and maintaining supersaturation than were rotoevaporated Drug/HPMCAS dispersions or physical mixtures of Drug and HPMCAS. The degree of achievable drug supersaturation increased with increasing polymer content in the SDD. The drug in Drug /HPMCAS SDDs was amorphous, and the dispersions were demonstrated to have a single glass transition and were thus homogeneous.
HPMCAS has been identified as a uniquely effective polymer for use in SDDs of low solubility drugs, with broad applicability across a variety of drug structures and properties.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
K. Johnson, and A. Swindell. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 13:1795–1798 (1996).
W. Curatolo. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Tech. Today. 1:387–393 (1998). doi:10.1016/S1461-5347(98)00097-2.
C. Lipinski, F. Lombardo, B. Dominy, and P. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Reviews. 23:3–25 (1997). doi:10.1016/S0169-409X(96)00423-1.
R. Gursoy, and S. Benita. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine & Pharmacother. 58:173–182 (2004). doi:10.1016/j.biopha.2004.02.001.
C. W. Pouton. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharmaceut. Sci. 29:278–287 (2006). doi:10.1016/j.ejps.2006.04.016.
C. J. Porter, C. W. Pouton, J. F. Cuine, and W. N. Charman. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv. Drug Del. Rev. 60:673–691 (2008). doi:10.1016/j.addr.2007.10.014.
C. W. Pouton, and C. J. Porter. Formulation of lipid-based delivery systems for oral administration: Materials, methods, and strategies. Adv. Drug Del. Rev. 60:625–637 (2008). doi:10.1016/j.addr.2007.10.010.
K. Sekiguchi, and N. Obi. Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixtures of sulphathiazole and that of ordinary sulphathiazole in man. Clin. Pharm. Bull. 9:866–872 (1961).
A. H. Goldberg, M. Gibaldi, and J. L. Kanig. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures I—theoretical considerations and discussions of the literature. J. Pharm. Sci. 54:1145–1148 (1965). doi:10.1002/jps.2600540810.
A. H. Goldberg, M. Gibaldi, and J. L. Kanig. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures II—experimental evaluation of a eutectic mixture: urea-acetaminophen system. J. Pharm. Sci. 55:482–487 (1966). doi:10.1002/jps.2600550507.
R. T. Stoll, T. R. Bates, K. A. Nieforth, and J. Swarbrick. Some physical factors affecting the enhanced blepharoptotic activity of orally administered reserpine-cholanic acid coprecipitates. J. Pharm. Sci. 58:1457–1459 (1969). doi:10.1002/jps.2600581206.
R. Stoll, T. Bates, and J. Swarbrick. In vitro dissolution and in vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates. J. Pharm. Sci. 62:65–68 (1973). doi:10.1002/jps.2600620111.
W. L. Chiou, and S. Riegelman. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J. Pharm. Sci. 58:1505–1510 (1969). doi:10.1002/jps.2600581218.
W. L. Chiou, and S. Riegelman. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60:1281–1302 (1971). doi:10.1002/jps.2600600902.
A. P. Simonelli, S. C. Mehta, and W. I. Higuchi. Dissolution rates of high energy sulfathiazole-povidone coprecipitates II—characterization of form of drug controlling its dissolution rate via solubility studies. J. Pharm. Sci. 65:355–361 (1976). doi:10.1002/jps.2600650310.
T. Higuchi, and R. Kuramoto. Study of possible complex formation between macromolecules and certain pharmaceuticals. J. Amer. Pharm. Assn. XLIII:393–397 (1954).
D. Horn, and W. Ditter. Chromatographic study of interactions between polyvinylpyrrolidone and drugs. J. Pharm. Sci. 71:1021–1026 (1982). doi:10.1002/jps.2600710917.
W. L. Chiou, and S. Riegelman. Oral absorption of griseofulvin in dogs: Increased absorption via solid dispersion in polyethyleneglycol 6000. J. Pharm. Sci. 59:937–942 (1970). doi:10.1002/jps.2600590703.
A. Serajuddin. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88:1058–1066 (1999). doi:10.1021/js980403l.
C. Leuner, and J. Dressman. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharmaceutics Biopharmaceutics. 50:47–60 (2000). doi:10.1016/S0939-6411(00)00076-X.
W. Curatolo, S. Herbig, and J. A. S. Nightingale. Solid pharmaceutical dispersions with enhanced bioavailability. European Patent EP-0901786B1, published March 17, 1999; granted June 13, 2007 (1999).
M. Crew, D. Friesen, B. Hancock, C. Macri, J. A. S. Nightingale, and R. M. Shanker. Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor. US Patent 7,235,260B2; International Patent WO-01/68092A2 Publication Date Sept. 20, 2001 (2001).
R. Beyerinck, H. Deibele, D. Dobry, R. Ray, D. Settell, and K. Spence. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus. US Patent Application 2003/0163931A1, published Sept. 4, 2003 (2003).
R. Beyerinck, D. Dobry, D. Friesen, D. Settell, and R. Ray. Spray drying processes for forming solid amorphous dispersions of drugs and polymers. US Patent Application 2005/0031692A1, published Feb. 10, 2005 (2005).
D. Friesen, R. Shanker, M. Crew, D. Smithey, W. Curatolo, and J. A. S. Nightingale. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Molec. Pharmaceut. 5:1003–1009 (2008). doi:10.1021/mp8000793.
M. Gordon, and J. S. Taylor. Ideal co-polymers and the second order transitions of synthetic rubbers. 1. Non-crystalline copolymers. J. Appl. Chem. 2:493–500 (1952).
W. C. Babcock, D. Friesen, J. A. S. Nightingale, and R. Shanker. Pharmaceutical solid dispersions. European Patent Application EP-1027886A2, published Aug. 16, 2000 (2000).
A. Dokoumetzidis, and P. Macheras. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System. International J. Pharmaceut. 321:1–11 (2006). doi:10.1016/j.ijpharm.2006.07.011.
D. Horter, and J. B. Dressman. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Del. Rev. 46:75–87 (2001). doi:10.1016/S0169-409X(00)00130-7.
E. Nicolaides, M. Symillides, J. B. Dressman, and C. Reppas. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18:380–388 (2001). doi:10.1023/A:1011071401306.
M. Carey, D. Small, and C. Bliss. Lipid digestion and absorption. Ann. Rev. Physiol. 45:651–677 (1983). doi:10.1146/annurev.ph.45.030183.003251.
O. Hernell, J. E. Staggers, and M.C. Carey. Physical–chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 29:2041–2056 (1990). doi:10.1021/bi00460a012.
W. Admirand, and D. M. Small. The physicochemical basis of cholesterol gallstone formation in man. J. Clin. Invest. 47:1043–1052 (1968).
J. Sjovall. Bile acids in man under normal and pathological conditions. Clin. Chem. Acta. 5:33–41 (1960). doi:10.1016/0009-8981(60)90086-3.
T. Northfield, and I. McColl. Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut. 14:513–518 (1973). doi:10.1136/gut.14.7.513.
W. C. Babcock, M. Crew, D. Friesen, M. Rabenstein, D. Smithey, and R. Shanker. Pharmaceutical compositions containing polymer and drug assemblies. European Patent Application WO-03/000226A2, published Jan. 3, 2003 (2003).
E. Jantratid, N. Janssen, C. Reppas, and J. B. Dressman. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25:1663–1676 (2008). doi:10.1007/s11095-008-9569-4.
The following colleagues did much of the initial work on screening, and on development of HPMCAS SDDs (including many of the formulations included in this paper) at Bend Research: Doug Lorenz, Gina Lorenz, Christi Hostetler, and Kathy Colombo Pugh. Initial spray drying apparatus development was done at Bend Research by Christi Hostetler and Doug Millard. We thank Karen Lillebo, Alison Viles, Ann Patten, and Holly Neighbarger of Bend Research for the dissolution tests. We are indebted to Scott McCray of Bend Research for assembling and organizing much of the data in this paper. We are pleased to acknowledge many helpful discussions with Dwayne Friesen and Chris Babcock of Bend Research, and Ravi Shanker of Pfizer. We gratefully acknowledge the enthusiastic support of David Dresback and Timothy Hagen of Pfizer.
About this article
Cite this article
Curatolo, W., Nightingale, J.A. & Herbig, S.M. Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu. Pharm Res 26, 1419–1431 (2009). https://doi.org/10.1007/s11095-009-9852-z
- bioavailability improvement
- hydroxypropylmethylcellulose acetate succinate
- low solubility drugs
- spray-dried dispersions